J&J lays out plans for 11 new drug approvals

With pharma sales beginning to slide and the loss of patent protection looming on its $2.5 billion a year epilepsy franchise from Topamax, Johnson & Johnson execs are spending much of today polishing up their late-stage development jewels for stock analysts.

J&J outlined upbeat plans to file for approval of three new drugs by the end of 2010 and up to eight more by the end of 2013. And the company told analysts that it expects to file for European approval of telaprevir and the leukemia drug Dacogen with a U.S. filing planned for the HIV drug TMC278.

J&J's psoriasis drug Stelara and the blood clot drug Xarelto--in development with Bayer--are both expected to win near-term FDA approval. Two weeks ago the FDA delayed its decision on Stelara for three months. And Johnson & Johnson is readying the launch of Tapentadol for moderate to severe pain. J&J has a total of seven drugs that are now awaiting final regulatory action. And with generics siphoning off a significant portion of its revenue stream, J&J execs are putting on an upbeat performance.

"We are very optimistic about our future," Sheri McCoy (photo), J&J's worldwide chairman of pharmaceuticals.

- read the story from Dow Jones
- read the report from Reuters

ALSO: J&J's experimental drug TMC207 demonstrated efficacy for drug-resistant TB in a small mid-stage study involving a cocktail of approved tuberculosis drugs. Report

Suggested Articles

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics’ CEO Aron Knickerbocker is exiting the company.

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…